Smith Corey, Khanna Rajiv
QIMR Centre for Immunotherapy and Vaccine Development and Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4029, Australia.
Tumour Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, 300 Herston Rd, Brisbane, 4006, Australia.
Curr Top Microbiol Immunol. 2015;391:455-73. doi: 10.1007/978-3-319-22834-1_16.
Over the last century, the development of effective vaccine approaches to treat a number of viral infections has provided the impetus for the continual development of vaccine platforms for other viral infections, including Epstein-Barr virus (EBV). The clinical manifestations associated with EBV infection occur either following primary infection, such as infectious mononucleosis, or following an extended period of latency, primarily the EBV-associated malignancies and potentially including a number of autoimmune disorders, such as multiple sclerosis. As a consequence, two independent vaccine approaches are under development to prevent or control EBV-associated diseases. The first approach, which has been widely successful against other viral infections, is aimed at inducing a viral neutralisation antibody response to prevent primary infection. The second approach focuses upon the induction of cell-mediated immunity to control latent infected cells in persistently infected individuals. Early clinical studies have offered some insight into the potential efficacy of both of these approaches.
在过去的一个世纪里，针对多种病毒感染开发有效疫苗方法的进展，为包括爱泼斯坦-巴尔病毒（EBV）在内的其他病毒感染的疫苗平台的持续发展提供了动力。与EBV感染相关的临床表现，要么发生在初次感染之后，如传染性单核细胞增多症，要么发生在长期潜伏之后，主要是EBV相关的恶性肿瘤，还可能包括一些自身免疫性疾病，如多发性硬化症。因此，目前正在开发两种独立的疫苗方法来预防或控制EBV相关疾病。第一种方法在对抗其他病毒感染方面已取得广泛成功，旨在诱导病毒中和抗体反应以预防初次感染。第二种方法侧重于诱导细胞介导的免疫反应，以控制持续感染个体中的潜伏感染细胞。早期临床研究已经对这两种方法的潜在疗效提供了一些见解。
